Retatrutide Heart Rate: How Much It Rises, Why, and When to Worry

Retatrutide raises your resting heart rate by a few beats per minute on average, and the rise grows with the dose. In the Phase 2 obesity trial published in the New England Journal of Medicine (NEJM), the retatrutide heart rate increase was dose-dependent, peaked at 24 weeks and declined after that. By the end of that 48-week trial, people on 12 mg averaged 6.0 beats per minute (bpm) above their starting pulse, against 0.4 bpm on placebo, according to a 2026 meta-analysis that tabulated the trial's figures.

As of October 2026, no approved version of retatrutide exists yet, and Lilly hasn't released a heart rate figure from any of its six Phase 3 readouts. So everything below is Phase 2 data, class evidence from the tirzepatide and semaglutide labels, or user reports.

Retatrutide heart rate changes, dose by dose

The NEJM abstract only describes the shape of the rise. These figures come from Table 1 of a 2026 network meta-analysis in the European Journal of Medical Research, which extracted them from the Phase 2 trial (NCT04881760). The 4 mg and 8 mg rows each combine two groups that started on different doses.

It climbs like a staircase, roughly 1.4 bpm per dose step by our math. For 1 mg and 4 mg the confidence range crosses zero, so those groups can't be told apart from placebo. At 8 mg and 12 mg the rise is clear.

Put it on your own pulse. If you sit at 70 bpm before starting, the 12 mg average takes you to about 76 bpm, inside the 60 to 100 bpm range MedlinePlus (NIH) gives as normal for adults at rest. The spread is wide, though: the standard deviation of the 12 mg change was 9.24 bpm.

Two caveats. These are end-of-trial numbers, and the rise peaked at week 24, so the peak was higher than this table shows; the full paper with that figure is paywalled. And none of Lilly's releases for its six Phase 3 readouts gives any heart rate data. The abstracts of the TRIUMPH-1 paper in NEJM and the TRIUMPH-2 paper in The Lancet don't either, and we couldn't read the full texts, so these Phase 2 figures are the only published numbers.

How it compares with tirzepatide and semaglutide

Every drug in this family nudges the pulse up. The same meta-analysis pooled placebo-controlled trials in people with overweight or obesity and no diabetes, putting retatrutide on one scale with the approved drugs. The label columns are class evidence from FDA prescribing information, not retatrutide data.

Only one retatrutide trial fed that pooled figure, against several for semaglutide and two for tirzepatide, so its range is wide. Tirzepatide has the lowest point estimate and retatrutide at 12 mg the highest, but the ranges overlap. Our retatrutide vs tirzepatide page covers the rest of that matchup, and retatrutide vs Mounjaro covers the diabetes brand.

The first head-to-head trial doesn't settle it. Lilly's October 28, 2026 TRANSCEND-T2D-2 release says retatrutide did better than Ozempic 2 mg on A1C, weight and systolic blood pressure, with no heart rate figure for either drug.

Our read: an average rise of 3 to 6 bpm is small next to the 60 to 100 bpm normal range, but averages hide the big jumps. About 1 extra person in 10 on semaglutide (26% vs 16%) hit a rise of 20 bpm or more at some visit, and retatrutide's top dose raises the average more, so your own before-and-after readings tell you more than any average.

Why does reta increase heart rate?

Retatrutide acts on three hormone receptors, GLP-1, GIP and glucagon, and two have a known line to the heart.

GLP-1 is the better understood of the two. In a 2024 study in Cardiovascular Research, GLP-1 sped up the heart in pigs even when the scientists cut the vagus nerve or gave beta-blockers, and it did the same in isolated hearts. They traced the effect to GLP-1 receptors on the pacemaker cells of the sinus node. That's the leading explanation for the whole class, though it was shown in pigs, not people.

Glucagon is the piece retatrutide adds. A 2025 lab study in Naunyn-Schmiedeberg's Archives of Pharmacology found retatrutide made isolated mouse right atrial tissue beat faster; a glucagon receptor blocker stopped it, and the beta-blocker propranolol didn't. A second 2025 study from the same journal used right atrial tissue from heart surgery patients, and retatrutide made it contract harder, again without beta receptors. That was force, not rate. Both are tissue in a dish, and nobody has published which receptor drives the rise in living people.

The pulse also goes up while blood pressure comes down. Falling pressure can speed the pulse by reflex, but isolated pig hearts have no nerve supply to carry a reflex, so a reflex doesn't explain all of it. Every Phase 3 readout reported a systolic pressure drop, none a pulse:

All figures are Lilly's efficacy estimand, meaning as if everyone had stayed on treatment. Pressure can drop too far for some: in the TRIUMPH-2 paper in The Lancet, hypotension was reported by 1% on 4 mg, 5% on 9 mg and 6% on 12 mg against fewer than 1% on placebo.

Does the faster pulse settle down?

Partly, going by Phase 2. The rise peaked at 24 weeks and declined afterward, per the NEJM authors. The last dose step came by week 12, so the pulse kept climbing for about 3 months after the dose stopped rising. How far it falls, and whether it gets back to your old baseline, is unknown: the 12 mg group was still 6.0 bpm up when the trial ended. Because the rise tracks dose, it belongs in any talk with your doctor about retatrutide dosage steps.

Timing within the week is unmapped too. Lilly Medical Information gives time to peak as 12 to 72 hours after a dose, and no study we found plots pulse across that cycle. Our half-life page has the curve.

What people using unverified vials report

Reddit is louder than the trials. A JAMA Network Open study (October 14, 2026) ran a language-model classifier over 148,640 retatrutide posts and comments. Of the 7,823 users with at least one mapped symptom, 374 (4.8%) reported a higher heart rate, 294 (3.8%) tachycardia, 146 (1.9%) palpitations and 49 (0.6%) a lower heart rate variability (HRV), the beat-to-beat timing that wearables score. A higher heart rate was among the seven most common terms, and the paper's comparison with an earlier semaglutide and tirzepatide social media study found retatrutide posts more concentrated in heart rate and pulse terms. These are self-reports about unverified products, with no verified doses or pulse readings.

Wearables score HRV and sleeping heart rate, but none of the retatrutide trial reports we read give either. Our retatrutide insomnia and retatrutide fatigue pages cover the sleep side.

An August 2026 preprint, not peer reviewed, found in health records a rise of 2.5 bpm at 3 months on compounded retatrutide that it did not see in matched semaglutide or tirzepatide users.

Palpitations, tachycardia and arrhythmia

Palpitations mean you notice your heartbeat: racing, pounding, fluttering, or skipping and adding beats, in the NHS's description. A higher resting rate is a different thing, and the trial data mostly covers that.

ClinicalTrials.gov lists every non-serious adverse event that reached 5% in any group of the two Phase 2 trials. No heart rate term made either list: no tachycardia, no palpitations, no "heart rate increased". The serious event tables, across the 457 people who took retatrutide in the two trials, show one atrial fibrillation (8 mg, diabetes trial), one prolonged QT on an ECG (12 mg, obesity trial) and three heart failure events (8 mg in the obesity trial; 0.5 mg and 4 mg in the diabetes trial). A handful of events in small groups can't show a link.

No retatrutide trial has published a count like Mounjaro's sinus tachycardia figure in the table above, and that label calls the clinical relevance of heart rate increases uncertain.

Can retatrutide cause heart problems?

The best evidence so far is TRIUMPH-3, which randomized 1,949 people with a BMI of 35 or more and established heart or blood vessel disease. Over 80 weeks, major heart events were rarer than expected in both groups. For MACE-5 (death from any cause, heart attack, stroke, heart failure event or a procedure to reopen a heart artery), there were 44 events on retatrutide against 52 on placebo, a hazard ratio of 0.82 (95% CI 0.55 to 1.22). For MACE-3 (cardiovascular death, heart attack or stroke) it was 27 against 23 (1.12, 0.64 to 1.96). Both ranges cross 1, so the trial could show neither harm nor benefit, and it has no journal paper yet.

TRIUMPH-Outcomes is built to answer it: about 10,000 people aged 45 or older with heart or kidney disease, followed for about 248 weeks, with primary completion estimated for February 2029. Until then, heart safety past 80 weeks is open; our long-term side effects page tracks it.

TRIUMPH-3 left out people who'd had a heart attack, stroke, artery-opening procedure or hospital stay for heart failure or unstable angina in the 90 days before screening. If you take a beta-blocker, Lilly ran a 30-person study (NCT06808802) on whether retatrutide changes how the body handles metoprolol; it finished in April 2025, and no results are posted as of October 2026.

A pulse far above these averages has one more explanation to rule out: the vial. Australia's TGA said in September 2026 that a product sold as retatrutide held no retatrutide, but semaglutide at about 8 times the level in approved products. Lilly says retatrutide is an investigational medicine that is not on the market, so any retatrutide for sale online isn't Lilly's product, and the trial numbers here may not describe what's inside it.

How to check your resting heart rate

This follows MedlinePlus:

1. Rest for at least 10 minutes first.
2. Find the pulse at your wrist or neck, count the beats for 30 seconds and double it, or count for a full minute.
3. Measure at the same time each day, before caffeine, which the NHS lists as a palpitation trigger.
4. Log a week of readings before your first dose, then keep logging through each dose increase and past week 24.
5. Note what else changed that day: a skipped meal, a bad night, a vomiting spell, the days since your injection. If you also take insulin or a sulfonylurea, low blood sugar can make your heart beat too fast or unevenly, per the NIDDK (NIH), so check your glucose.

Take the log to appointments, not one reading. The Wegovy label tells prescribers to check heart rate at regular intervals and to stop semaglutide if resting heart rate stays raised. That's class advice, but it's the closest rule on paper. Our is retatrutide safe page puts the heart data next to everything else.

When to get medical help

See a doctor soon, rather than urgently, if:

• palpitations keep coming back, happen more often or last more than a few minutes (NHS)
• your resting rate stays above 100 bpm, the top of the normal adult range per MedlinePlus
• you have a heart condition or a family history of heart problems (NHS)
• your resting pulse is still well above your pre-reta baseline after week 24, when the Phase 2 rise was already easing

Bring the log, your dose-change dates and any wearable readings, and say exactly what you're taking and where it came from.